USD 2.07
(-3.72%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 6.51 Million USD | -89.46% |
2022 | 61.8 Million USD | -27.94% |
2021 | 85.75 Million USD | 33.25% |
2020 | 64.35 Million USD | 923.03% |
2019 | 6.29 Million USD | -24.75% |
2018 | 8.36 Million USD | 108.63% |
2017 | 4 Million USD | 3867.33% |
2016 | 101 Thousand USD | 3266.67% |
2015 | 3000.00 USD | -99.96% |
2014 | 7.01 Million USD | 58350.0% |
2013 | 12 Thousand USD | -25.0% |
2012 | 16 Thousand USD | -30.43% |
2011 | 23 Thousand USD | 0.0% |
2010 | - USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2023 Q2 | 1.79 Million USD | -50.1% |
2023 Q1 | 3.59 Million USD | -71.88% |
2023 FY | 6.51 Million USD | -89.46% |
2022 Q3 | 17.55 Million USD | -4.33% |
2022 Q1 | 18.23 Million USD | -17.38% |
2022 Q2 | 18.34 Million USD | 0.6% |
2022 FY | 61.8 Million USD | -27.94% |
2022 Q4 | 12.79 Million USD | -27.09% |
2021 Q2 | 21.5 Million USD | 4.51% |
2021 Q3 | 21.6 Million USD | 0.5% |
2021 Q4 | 22.07 Million USD | 2.14% |
2021 FY | 85.75 Million USD | 33.25% |
2021 Q1 | 20.57 Million USD | -4.13% |
2020 FY | 64.35 Million USD | 923.03% |
2020 Q1 | 1.05 Million USD | -33.58% |
2020 Q2 | 20.89 Million USD | 1879.07% |
2020 Q3 | 20.94 Million USD | 0.21% |
2020 Q4 | 21.46 Million USD | 2.47% |
2019 Q3 | 1.4 Million USD | -10.36% |
2019 Q1 | 1.73 Million USD | 27.81% |
2019 Q2 | 1.56 Million USD | -10.02% |
2019 FY | 6.29 Million USD | -24.75% |
2019 Q4 | 1.59 Million USD | 13.49% |
2018 FY | 8.36 Million USD | 108.63% |
2018 Q4 | 1.35 Million USD | -38.4% |
2018 Q3 | 2.2 Million USD | -6.13% |
2018 Q2 | 2.35 Million USD | -3.89% |
2018 Q1 | 2.44 Million USD | 22.19% |
2017 Q3 | 1.52 Million USD | 215.32% |
2017 Q4 | 2 Million USD | 31.39% |
2017 FY | 4 Million USD | 3867.33% |
2017 Q2 | 483 Thousand USD | 0.0% |
2017 Q1 | - USD | -100.0% |
2016 FY | 101 Thousand USD | 3266.67% |
2016 Q4 | 100 Thousand USD | 0.0% |
2016 Q3 | - USD | -100.0% |
2016 Q2 | 1000.00 USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2015 Q1 | 1000.00 USD | 0.0% |
2015 FY | 3000.00 USD | -99.96% |
2015 Q4 | - USD | -100.0% |
2015 Q3 | 1000.00 USD | 0.0% |
2015 Q2 | 1000.00 USD | 0.0% |
2014 FY | 7.01 Million USD | 58350.0% |
2014 Q4 | 1000.00 USD | -75.0% |
2014 Q2 | 4000.00 USD | -99.94% |
2014 Q1 | 7 Million USD | 700400.0% |
2014 Q3 | 4000.00 USD | 0.0% |
2013 FY | 12 Thousand USD | -25.0% |
2013 Q2 | 4000.00 USD | 0.0% |
2013 Q1 | 4000.00 USD | 0.0% |
2013 Q3 | 3000.00 USD | -25.0% |
2013 Q4 | 1000.00 USD | -66.67% |
2012 Q4 | 4000.00 USD | 33.33% |
2012 Q1 | 4000.00 USD | 33.33% |
2012 Q3 | 3000.00 USD | -40.0% |
2012 Q2 | 5000.00 USD | 25.0% |
2012 FY | 16 Thousand USD | -30.43% |
2011 FY | 23 Thousand USD | 0.0% |
2011 Q3 | 11 Thousand USD | 0.0% |
2011 Q4 | 3000.00 USD | -72.73% |
2010 FY | - USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Esperion Therapeutics, Inc. | 116.33 Million USD | 94.401% |
Theratechnologies Inc. | 81.76 Million USD | 92.034% |
Safety Shot Inc | 202.67 Thousand USD | -3113.684% |
Cosmos Health Inc. | 53.37 Million USD | 87.798% |
Cronos Group Inc. | 88.84 Million USD | 92.669% |
Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 98.529% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Organogenesis Holdings Inc. | 433.14 Million USD | 98.496% |
Universe Pharmaceuticals INC | 32.3 Million USD | 79.841% |
ProPhase Labs, Inc. | 44.38 Million USD | 85.325% |
Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 48.856% |
Dynavax Technologies Corporation | 232.28 Million USD | 97.196% |
Radius Health, Inc. | 2.88 Billion USD | 99.774% |
China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -237.733% |
Alvotech | 91.43 Million USD | 92.877% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 72.966% |
Alpha Teknova, Inc. | 36.68 Million USD | 82.245% |
Intra-Cellular Therapies, Inc. | 464.37 Million USD | 98.597% |
SCYNEXIS, Inc. | 140.14 Million USD | 95.352% |
Harrow Health, Inc. | 130.19 Million USD | 94.997% |
Biofrontera Inc. | 34.07 Million USD | 80.884% |
DURECT Corporation | 8.54 Million USD | 23.805% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 98.928% |
ANI Pharmaceuticals, Inc. | 486.81 Million USD | 98.662% |
OptiNose, Inc. | 70.98 Million USD | 90.825% |
Aquestive Therapeutics, Inc. | 50.58 Million USD | 87.124% |
Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 83.533% |
SIGA Technologies, Inc. | 139.91 Million USD | 95.345% |
Lifecore Biomedical, Inc. | 128.26 Million USD | 94.922% |
Shineco, Inc. | 9.8 Million USD | 33.552% |
Phibro Animal Health Corporation | 1.01 Billion USD | 99.36% |
Procaps Group S.A. | 409.92 Million USD | 98.411% |
TherapeuticsMD, Inc. | 1.3 Million USD | -400.244% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Viatris Inc. | 15.42 Billion USD | 99.958% |
Sunshine Biopharma, Inc. | 24.09 Million USD | 72.966% |
Rockwell Medical, Inc. | 83.61 Million USD | 92.21% |
Incannex Healthcare Limited | 12 Thousand USD | -54176.442% |
Aytu BioPharma, Inc. | 81 Million USD | 91.959% |
Tilray Brands, Inc. | 788.94 Million USD | 99.174% |
Collegium Pharmaceutical, Inc. | 566.76 Million USD | 98.851% |
PetIQ, Inc. | 1.1 Billion USD | 99.409% |
Silver Spike Investment Corp. | 11.72 Million USD | 44.437% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.655% |
Journey Medical Corporation | 79.18 Million USD | 91.774% |
Alimera Sciences, Inc. | 80.75 Million USD | 91.935% |
Petros Pharmaceuticals, Inc. | 5.82 Million USD | -11.864% |
Assertio Holdings, Inc. | 152.06 Million USD | 95.717% |
Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Embecta Corp. | 1.12 Billion USD | 99.419% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -505.086% |
Procaps Group, S.A. | 409.92 Million USD | 98.411% |
PainReform Ltd. | - USD | -Infinity% |
Avadel Pharmaceuticals plc | 27.96 Million USD | 76.708% |
Hempacco Co., Inc. | 4.04 Million USD | -60.993% |
Talphera, Inc. | 651 Thousand USD | -900.487% |
Pacira BioSciences, Inc. | 674.97 Million USD | 99.035% |
Alvotech | 91.43 Million USD | 92.877% |
Lantheus Holdings, Inc. | 1.29 Billion USD | 99.498% |
Kamada Ltd. | 144.75 Million USD | 95.501% |
Indivior PLC | 1.09 Billion USD | 99.404% |
Currenc Group, Inc. | 53.25 Million USD | 87.77% |
Evoke Pharma, Inc. | 5.18 Million USD | -25.722% |
Flora Growth Corp. | 76.07 Million USD | 91.438% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -505.086% |
Evolus, Inc. | 202.08 Million USD | 96.777% |
HUTCHMED (China) Limited | 837.99 Million USD | 99.223% |
Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 98.989% |
Akanda Corp. | 2.16 Million USD | -201.529% |